A large national retail pharmacy chain developed a patientcentric program providing enhanced levels of monitoring and care for patients taking MS Specialty Drugs as dispensed in a retail setting. MS biologics covered in the ConnectedCare for Multiple Sclerosis (CCMS) program during this analysis period included Avonex, Betaseron, Copaxone, Extavia, and Rebif. OBJECTIVES: To compare adherence rates for MS biologics between managed and nonmanaged patients new to retail pharmacy or the CCMS program. The effect of health complications on adherence rates was also assessed. METHODS: This was a retrospective analysis of MS patients new to therapy (or pharmacy chain) during the initial six months of CCMS. Patients were followed for one year. Adherence was measured using proportion of days covered (PDC). For the primary objective, propensity scores based on patients' gender, age, presence of chronic comorbidities, and pre-study adherence to chronic medications were used to match the CCMS intervention group to a comparisons group. Sub-group analysis on health complications (chronic medication comorbidity, or assessment screenings for depression and fatigue) used Analysis of Covariance to adjust for the propensity variables when examining PDC in the presence of health complications across managed cohorts. RESULTS: Mean PDC was nearly 10% higher for the managed CCMS patients than for non-managed patients. Patients not managed with at least one chronic comorbidity had about an 11% lower PDC than non-managed patients without a comorbid condition, whereas, managed patients indicated little difference in relation to the presence of a comorbidity. Adherence levels were also reduced for non-managed patients reporting fatigue and depression, yet self-reports of fatigue and depression did not significantly affect adherence levels among managed patients. CONCLUSIONS: The provision of medication therapy management for MS patients significantly increases adherence to MS biologic medications. Among non-managed patients, adherence is even further reduced among patients with fatigue and depression.
OBJECTIVES:
To assess the clinical and economic burden of Alzheimer's disease in the U.S. veteran population. METHODS: Data from the Veterans Health Administration (VHA) Medical SAS Datasets was used to conduct a retrospective study (October 1, 2005 -May 31, 2012 . Patients diagnosed with Alzheimer's disease throughout the study period were identified using International Classification of Disease 9 th Revision Clinical Modification (ICD-9-CM) diagnosis code 331.0. Health care resource utilization and costs were assessed in the 12month follow-up period, and clinical status was examined for the 12-month baseline period before disease identification. Major treatments during the 60 days after disease identification were also studied. All descriptive statistical analyses were performed using SAS v9.3 software. RESULTS: A total of 54,161 Alzheimer's disease patients were identified in the VHA population during the study period. The most common comorbidities for Alzheimer's disease patients were hypertension (n=14,387, 26.56%), followed by mental disorders (n=13,440, 24.81%), diabetes (n=7,440, 13.74%) and memory loss (n=4,850, 8.95%). Other comorbidities included senile dementia and hearing loss. The top three treatments for Alzheimer's disease were donepezil hydrochloride (n=16,526, 30.51%), simvastatin (n=16,010, 29.56%), and memantine (n=11,081, 20.46%). Outpatient services were utilized by 98.62% of Alzheimer's patients, followed by pharmacy (86.75%) and inpatient visits (30.29%). Outpatient ($7,650, [standard deviation] SD=$12,539), pharmacy ($1,660, SD=$2,688), and inpatient costs ($16, 790, SD=$75, 963) contributed to follow-up health care expenditures. CONCLUSIONS: The U.S. veteran Alzheimer's disease patient population had high percentages of comorbid conditions, including hypertension and mental disorders, as well as outpatient and inpatient visits. Further analysis is needed to evaluate the extent to which the treatment of Alzheimer's disease is complicated by the presence of these comorbidities. (SD=$7, 285) , and $9,171 (SD=$57,129), respectively. CONCLUSIONS: MS treatment is complicated by the presence of comorbidities. Further analysis in the context of complicated comorbid condition diagnoses is required to improve the overall burden of illness of MS patients.
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COMORBIDITIES AND ECONOMIC BURDEN OF MULTIPLE SCLEROSIS PATIENTS IN THE UNITED STATES VETERAN POPULATION
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VALIDATION OF A CHINESE VERSION OF NEUROPSYCHIATRY UNIT COGNITIVE ASSESSMENT TOOL (NUCOG)
Gao L 1 , Walterfang M 2 , Velakoulis D 2 , Li SC 1 1 University of Newcastle, Callaghan, Australia, 2 Royal Melbourne Hospital, Melbourne, Australia OBJECTIVES: To validate a Chinese version of NUCOG METHODS: Accepted translation procedures were followed to develop a Chinese version of NUCOG. Patients from two hospitals were recruited between July and October, 2012. Statistical analysis was performed using SPSS 20.0. Subgroup analysis according to diagnosis was performed. Receiver Operating Characteristic (ROC) curves were utilized to test criterion validity. Convergent validity was assessed via correlations between NUCOG and MMSE and internal consistency was measured to test the reliability. RESULTS: 529 subjects comprised of patients with epilepsy (n=144), neurological diseases (n=81), dementia (n=44), control group (n=260) completed NUCOG and MMSE. Overall, both NUCOG and MMSE scores differed significantly across four groups with dementia<epilepsy=neurology<controls (p<0.0001). The subscale-by-group analysis of NUCOG indicated different cognitive patterns for four groups, with patient groups scoring lowest in memory and executive domains. All the four groups achieved higher scores in the language domain than in other domains. The NUCOG, but not the MMSE, discriminated between patients with simple partial and secondary generalized/tonic-clonic generalized seizures, stroke and Transient Ischemic Attack (TIA). Compared to the MMSE, the NUCOG exhibited higher area under the ROC curve (0.969 vs. 0.915) to detect dementia among patients. A premium cutoff score of 70.5 gave a sensitivity of 0.955 and specificity of 0.875 to detect dementia in the patient groups for NUCOG. The convergent validity was substantially correlated across entire sample, with Spearman's r of 0.787 (p<0.0001). Internal consistency of NUCOG by Cronbach's α was 0.922. CONCLUSIONS: The Chinese version of NUCOG was demonstrated to be a sensitive, reliable screening tool for cognitive impairment. NUCOG could also better differentiate patients with certain seizure types, stroke and TIA compared to the MMSE. This would potentially expand the clinical usefulness of NUCOG in enabling clinicians to measure the cognitive profile of patients with epilepsy and ischemic cerebrovascular diseases.
PND10 PREDICTING THE LONG-TERM CLINICAL EFFECTIVENESS OF DACLIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A NEW MODELING FRAMEWORK USING DISCRETE EVENT SIMULATION
Guo S 1 , Hernandez L 1 , Saint-Laurent Thibault C 1 , Proskorovsky I 2 , Phillips GA 3 1 United BioSource Corporation, Lexington, MA, USA, 2 United BioSource Corporation, Dorval, QC, Canada, 3 Biogen Idec Inc., Weston, MA, USA OBJECTIVES: SELECT, a one-year phase II randomized controlled trial (RCT), showed benefits for daclizumab high-yield process 150mg (DAC HYP) versus placebo on relapses and disability among patients with relapsing-remitting multiple sclerosis (RRMS). This analysis utilized discrete-event simulation (DES) to model the potential long-term clinical implications of this trial. METHODS: An RRMS DES model that predicts the course of relapses, disability progression/regression, conversion to secondary-progressive MS (SPMS), and death was developed. During the RR phase, the occurrence of relapses could lead to change in patient's Expanded Disability Status Scale (EDSS) scores, which in turn influences the risk of relapses. Both endpoints are predicted based on treatment and other predictors using two interrelated equations derived from four RCTs of RRMS patients (n=4,189), including SELECT, AFFIRM, CONFIRM, and DEFINE. Treatment can be stopped for various reasons and was assumed to have no residual effect at discontinuation. Conversion to SPMS or death could occur at any time and are predicted based on patient's EDSS scores and other relevant characteristics using published epidemiological data. RESULTS: Over 20 years, patients on DAC HYP were predicted to result in: i) fewer relapses per patient (5.1 vs. 7.2); ii) a higher proportion of patients free of any relapse (24% vs. 16%); iii) a lower percent of patients progressing to SPMS (69% vs. 74%), and iv) more time spent in less severe disability states (15.1 vs. 14.3 years in EDSS<7) compared to those without treatment. Life expectancy was also longer for patients on DAC HYP, but the difference was small. These outcomes were most sensitive to model time horizon. CONCLUSIONS: Long-term modeling based on the SELECT trial outcomes suggests that DAC HYP has a positive impact on key outcome measures of interest to patients with RRMS and their clinicians. Evidence from its phase III trial is still needed to support its use. 
PND11 AN INTEGRATED ANALYSIS OF RELAPSES REQUIRING INTRAVENOUS STEROID USE AND MULTIPLE SCLEROSIS (MS)-RELATED HOSPITALIZATIONS FROM THE BG-12 (DIMETHYL FUMARATE) PHASE 3 DEFINE AND CONFIRM STUDIES
OBJECTIVES:
To report the effect of BG-12 (dimethyl fumarate) in reducing the number of relapses requiring intravenous (IV) steroids and multiple sclerosis (MS)-related hospitalizations from a pre-specified integrated analysis of DEFINE and CONFIRM, which was designed to estimate-more precisely-the therapeutic effect of BG-12 versus placebo. METHODS: Eligible patients were aged 18-55 years with relapsing-remitting MS (McDonald criteria) and an Expanded Disability Status Scale score of 0-5.0. Patients who received oral BG-12 240 mg twice (BID) or three times daily (TID) or placebo were included and the integrated analysis was to be conducted only if baseline characteristics and treatment effects were similar between the studies. Numbers of relapses requiring IV steroids and MS-related hospitalizations (tertiary endpoints in DEFINE and CONFIRM) were assessed. RESULTS: The integrated analysis included 769, 761, and 771 patients who received BG-12 BID, TID, and placebo, respectively. Baseline characteristics and treatment effects were generally similar between DEFINE and CONFIRM. There were significantly fewer relapses requiring steroids and MS-related hospitalizations in both BG-12 groups compared with placebo. BG-12 reduced the annualized rate of relapses requiring IV steroids by 48% (BID; rate ratio, 0.52 [95% confidence interval, 0.43-0.64]) and 50% (TID; 0.50 [0.41-0.61]) versus placebo (both p<0.0001) and reduced the annualized rate of MS-related hospitalizations by 34% (BID; 0.66 [0.47-0.92]; p=0.0146) and 47% (TID; 0.53 [0.37-0.75]; p=0.0004) at 2 years. CONCLUSIONS: BG-12 significantly reduced the number of relapses requiring IV steroids and MS-related hospitalizations, which suggests benefits with regard to patient burden and health economic savings due to decreased resource utilization. These findings further support the efficacy results of DEFINE and CONFIRM.
PND12 THE EFFICACY AND TOLERABILITY OF PERAMPANEL COMPARED TO OTHER ADJUNCTIVE RECENTLY APPROVED ANTI-EPILEPTIC DRUGS (AEDS) FOR THE TREATMENT OF REFRACTORY PARTIAL ONSET SEIZURES: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS (NMA)
Tongbram V 1 , Khan N 1 , Shah D 1 , Fortier KJ 1 , Hawkins N 2 1 Oxford Outcomes, Morristown, NJ, USA, 2 Oxford Outcomes, Oxford, UK OBJECTIVES: Perampanel (PER) is the first orally active α-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist approved for the adjunctive treatment of partial-onset seizures in patients with epilepsy aged 12 years and older. While the regulatory approval was on the basis of 3 RCTs, which demonstrated the efficacy and acceptable safety of perampanel relative to placebo, for the purpose of funding and health technology assessment decisions comparisons to other similar AED are necessary.The aim is to compare the clinical efficacy and tolerability of PER relative to other recently approved AEDs (lacosamide (LCM), retigabine (RTG), and eslicarbazepine (ESL)) for the adjunctive treatment of partial onset seizures with or without secondarily generalization. METHODS: A systematic literature review was conducted to identify all RCTs of PER and selected AEDs. EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials from 1998 to September 2011, abstracts from selected 2010 and 2011 conferences, reference lists of included studies and unpublished study reports were searched. The odds-ratio for three outcomes: ">50% reduction in seizure frequency", "seizure freedom" and "withdrawal due to adverse events" were estimated using fixed-and random-effects Bayesian NMA models. RESULTS: Twelve RCTs (3 PER, 3 LCM, 3 RTG and 3 ESL) met the inclusion criteria. In the analysis for ">50% reduction in seizure frequency", all AEDs performed significantly better than placebo with odds-ratio for PER being similar to the other comparators. In the analysis for "seizure freedom", all AEDs except LCM performed significantly better than placebo. In the analysis for "withdrawal due to adverse events" PER had the lowest odds-ratio compared to other AEDs. No significant difference was observed in any of the three outcomes between PER and the other AEDs when compared against each other. CONCLUSIONS: Compared with other licensed adjunctive AEDs, perampanel offers similar clinical efficacy and tolerability profile. Treatment and Research, Cleveland Clinic, Cleveland, OH, USA, 3 St Josef Hospital, Bochum, Germany, 4 University College London Institute of Neurology, London, UK, 5 Montreal Neurological Institute and Hospital; and NeuroRx Research, Montreal, QC, Canada, 6 Biogen Idec Inc., Weston, MA, USA, 7 St Vincent's University Hospital, Dublin, Ireland OBJECTIVES: To report efficacy of BG-12 (dimethyl fumarate) in pre-specified patient subgroups stratified by age, gender, treatment history, prior relapses, Expanded Disability Status Score (EDSS), McDonald criteria, T2 lesion volume, and presence/absence of gadolinium-enhancing lesions at baseline in a prespecified integrated analysis of DEFINE and CONFIRM. This analysis was designed to estimate-more precisely-the treatment effect of BG-12 versus placebo. METHODS: Eligible patients were aged 18-55 years with a diagnosis of relapsing-remitting multiple sclerosis (RRMS) (McDonald criteria) and an EDSS score of 0-5.0. Patients receiving BG-12 240 mg twice (BID) or three times daily (TID) or placebo were included in this analysis. Primary endpoints were proportion of patients relapsed (DEFINE) and annualized relapse rate (ARR) (CONFIRM) at 2 years. Secondary endpoints included number of new/enlarging T2 lesions and disability progression. The pre-specified integrated analysis was to be conducted only if baseline characteristics and treatment effects were consistent between the studies. RESULTS: The integrated intent-to-treat population comprised 2,301 patients while MRI evaluations were performed in a cohort of 1,046 patients. Baseline characteristics and treatment effects were generally similar across studies. Both BG-12 BID and TID reduced ARR versus placebo at 2 years by approximately 50%, risk of relapse, number of new/enlarging T2 lesions, and risk of disability progression at 2 years versus placebo across the subgroups. For example, ARR versus placebo at 2 years was reduced by 50% (BID; rate ratio 0.50 [95% confidence interval 0.40-0.64]) and 53% (TID; 0.47 [0.37-0.60]) in patients with ≤1 relapse in the year before study entry and 47% (BID; 0.53 [0.40-0.72]) and 41% (TID; ) in patients with ≥2 relapses. CONCLUSIONS: These findings further indicate consistent efficacy of BG-12 on both clinical and neuroradiological measures across a wide spectrum of RRMS patients.
PND13 CLINICAL AND NEURORADIOLOGICAL EFFECT OF BG-12 (DIMETHYL FUMARATE) IN SUBGROUPS OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF THE PHASE 3 DEFINE AND CONFIRM STUDIES
PND14 PROPENSITY SCORE ANALYSIS IN MEPS 2003-2010: PCS AND MCS SCORES AFTER MIGRAINE TREATMENTS
Wu IH, Johnson ML, Aparasu RR University of Houston, Houston, TX, USA OBJECTIVES: Migraine is a public health problem that has an impact on both the individual sufferer and on society. The objective of this study was to examine the PCS (physical component summary) and MCS (mental component summary) score after being treated with one of the two different recommended level A medications -Triptans and Anti-epileptics. METHODS: MEPS data 2003 MEPS data -2010 were downloaded from the AHRQ website. Migraine patients who started to receive either Triptans or Anti-epileptics in round 3 were retained in the cohort. Patients who received combination therapy or received the medication in round 1 or 2 were excluded in order to control for the baseline characteristics. Propensity score method was used to ensure the patients being compared are equal within each tertile. The predicted probability of receiving Triptans was calculated for all patients in the cohort by using multiple logistic regression to control for demographics, comorbidity and PCS/MCS in round 2. The probabilities were then stratified into tertiles. The outcomes -PCS and MCS in round 4 were compared within each tertile to examine if there were any differences between the two medications. RESULTS: Overall there were 120 patients in the cohort with weighted frequency of 2,779,074 (2,049,642 for Triptans and 729,432 for Anti-epileptics). After the propensity score stratification, all the baseline information between the two treatment cohorts were equal in each tertile except race in tertile 2 (p=0.0124). After the outcomes comparison, there were no differences in round 4 PCS and MCS score between the two medications for all three tertiles. CONCLUSIONS: Triptans are the most expensive among all the migraine medications. However, the findings of our study demonstrated there were no differences in PCS and MCS after the treatment. Future studies should examine different outcomes and see if Triptans can improve other clinical findings.
PND15 MULTIPLE SCLEROSIS EARLY TREATMENT RATES IN UNITED STATES VETERANS
Xie Y 1 , Lafleur J 1 , Kamauu A 2 , Schuerch M 3 , Foskett N 3 , Nelson RE 1 1 University of Utah, Salt Lake City, UT, USA, 2 Anolinx, LLC, Salt Lake City, UT, USA, 3 F. Hoffman-La Roche Ltd, Basel, Switzerland OBJECTIVES: Multiple sclerosis (MS) is a common autoimmune demyelinating disease of the central nervous system. Early treatment of MS aids in repressing the most severe stage of acute axonal injury. The objective of this study was to characterize the proportion of MS patients who received early treatment, defined as an immunosuppressive treatment within 12 months following diagnosis. METHODS: We identified patients with an MS diagnosis who sought care in the US Veterans Health Administration (VHA) system from 1999-2010. The index date was the date of firs MS diagnosis. Patients who did not have at least 12 months of follow-up time were excluded. Descriptive statistics were used to characterize prescriptions for medications commonly used to treat MS in the 12 months following the index date. RESULTS: Our analysis cohort consisted of 6,011 MS patients. Mean age was 53.8 (SD 13.4) years and 80.7% were male. Race was known in 40.8%; of which most were white (80.2%) or black (16.0%). Only 35.3% of MS patients had a prescription for MS treatment in the 12 months following the index date. The most common MS treatments among MS patients were interferon beta 1a (13.2%), glatiramer (10.3%), amantadine (6.9%), prednisone (6.5%), and methylprednisolone (5.5%). Younger patients were more likely to have prescriptions. In a subset of 3,312 patients age <55, e.g., those who would be eligible for a clinical trial, 44.1% had a prescription for any immunosuppressive therapy used to treat MS. Interferon beta 1a (17.9%) was the most common treatment in this subgroup followed by glatiramer (13.6%), amantadine (8.9%), methylprednisolone (7.3%), and prednisone (6.8%). CONCLUSIONS: This descriptive analysis indicates that most patients with a diagnosis of MS do not receive early immunosuppressive therapy. Future research should identify relevant barriers to treatment and potential solutions to overcoming these barriers.
